Kane Biotech Inc. (CVE:KNE – Get Free Report) traded down 14.3% during mid-day trading on Friday. The stock traded as low as C$0.03 and last traded at C$0.03. 111,975 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 149,634 shares. The stock had previously closed at C$0.04.
Kane Biotech Stock Down 14.3%
The firm has a market cap of C$6.15 million, a price-to-earnings ratio of -1.50 and a beta of 0.60. The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The stock has a 50-day moving average of C$0.03 and a 200-day moving average of C$0.03.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Recommended Stories
- Five stocks we like better than Kane Biotech
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
